I fase III RESIST- forsøgene var frekvensen af forhøjet transaminase signifikant forøget i APTIVUS/ ritonavir- gruppen sammenlignet med komparatorgruppen.
In Phase III RESIST trials, the frequency of transaminase elevations was significantly increased in the APTIVUS/ ritonavir arm compared to the comparator arm.